Aldactazide, Qaialdo(spironolactone)
Aldactazide, Aldactone, Carospir, Qaialdo, Spironolactone (spironolactone) is a small molecule pharmaceutical. Spironolactone was first approved as Spironolactone and hydrochlorothiazide on 1982-01-01. It is used to treat ascites, edema, heart failure, hirsutism, and hyperaldosteronism amongst others in the USA. It has been approved in Europe to treat ascites, edema, essential hypertension, heart failure, and hyperaldosteronism amongst others. The pharmaceutical is active against mineralocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Aldactone, Carospir (generic drugs available since 1982-01-01)
CombinationsAldactazide (generic drugs available since 1982-01-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 011503 dapsone 6% / niacinamide 2% / spironolactone 5% | unapproved drug other | 2020-07-02 |
| aldactazide | New Drug Application | 2023-11-23 |
| benzoyl peroxide 5% / clindamycin 1% / niacinamide 2% / spironolactone 2% | unapproved drug other | 2019-05-10 |
| benzoyl peroxide 5% / clindamycin 1% / niacinamide 2% / spironolactone 2% / tretinoin 0.025% | unapproved drug other | 2019-05-03 |
| benzoyl peroxide 5% / clindamycin 1% / niacinamide 2% / spironolactone 2% / tretinoin 0.05% | unapproved drug other | 2019-05-02 |
| clindamycin 1% / niacinamide 4% / spironolactone 2% / tretinoin 0.025% | unapproved drug other | 2020-06-04 |
| dapsone 6% / niacinamide 2% / spironolactone 5% | unapproved drug other | 2019-05-10 |
| dapsone 8.5% / niacinamide 2% / spironolactone 5% | unapproved drug other | 2019-05-09 |
| spironolactone and hydrochlorothiazide | ANDA | 2023-12-05 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
285 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | 3 | 8 | 12 | 17 | 14 | 51 |
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 7 | 4 | 17 | 11 | 41 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | 3 | 2 | 3 | 2 | 9 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | 1 | 6 | — | 8 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 3 | — | 2 | 3 | 8 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | 1 | 3 | 3 | 8 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 2 | 3 | 1 | 2 | 7 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 2 | 1 | 1 | 2 | 6 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | 1 | — | 2 | 2 | 5 |
| Hyperkalemia | D006947 | HP_0002153 | E87.5 | — | 2 | 1 | 2 | — | 5 |
Show 44 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | 1 | — | 10 | 11 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | 2 | 4 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 1 | 2 | — | 1 | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | 2 | 3 |
| St elevation myocardial infarction | D000072657 | — | — | — | — | 2 | — | 1 | 3 |
| Bronchopulmonary dysplasia | D001997 | — | P27.8 | — | 1 | 1 | — | 1 | 2 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | 1 | 1 | — | 1 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 2 | 1 | — | — | 2 |
| Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | 1 | — | 1 | — | — | 2 |
| Critical illness | D016638 | — | — | — | 1 | 1 | — | 1 | 2 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 4 | 2 | — | — | 3 | 9 |
| Essential hypertension | D000075222 | — | I10 | — | 1 | — | — | 2 | 3 |
| Gender identity | D005783 | — | — | 1 | 1 | — | — | 2 | 3 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 2 | — | — | — | 2 |
| Arrhythmogenic right ventricular dysplasia | D019571 | Orphanet_247 | I42.8 | — | 1 | — | — | — | 1 |
| Behavior and behavior mechanisms | D001520 | — | — | 1 | 1 | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 1 | — | — | — | 1 |
| Acanthosis nigricans | D000052 | — | L83 | — | 1 | — | — | — | 1 |
| Ischemic stroke | D000083242 | — | — | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperandrogenism | D017588 | — | — | 2 | — | — | — | — | 2 |
| Puberty | D011627 | EFO_0001382 | — | 2 | — | — | — | — | 2 |
| Gender dysphoria | D000068116 | — | F64 | 1 | — | — | — | — | 1 |
| Glucose metabolism disorders | D044882 | — | — | 1 | — | — | — | — | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 1 | — | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | — | — | — | — | 1 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 1 | — | — | — | — | 1 |
| Melanosis | D008548 | HP_0001480 | L81.1 | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Takotsubo cardiomyopathy | D054549 | EFO_1002000 | I51.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypokalemia | D007008 | HP_0002900 | E87.6 | — | — | — | — | 3 | 3 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 2 | 2 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 2 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 2 | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | — | 2 | 2 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 2 | 2 |
| Coronary disease | D003327 | — | — | — | — | — | — | 2 | 2 |
| Sudden death cardiac | D016757 | EFO_0004278 | — | — | — | — | — | 2 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
Show 56 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Spironolactone |
| INN | spironolactone |
| Description | Spironolactone is a steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7. It has a role as a diuretic, an aldosterone antagonist, an antihypertensive agent, an environmental contaminant and a xenobiotic. It is a steroid lactone, an oxaspiro compound, a thioester and a 3-oxo-Delta(4) steroid. |
| Classification | Small molecule |
| Drug class | Antimineralocorticoid; Steroidal antiandrogen |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21 |
Identifiers
| PDB | — |
| CAS-ID | 52-01-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1393 |
| ChEBI ID | 9241 |
| PubChem CID | 5833 |
| DrugBank | DB00421 |
| UNII ID | 27O7W4T232 (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C2
NR3C2
Organism
Homo sapiens
Gene name
NR3C2
Gene synonyms
MCR, MLR
NCBI Gene ID
Protein name
mineralocorticoid receptor
Protein synonyms
aldosterone receptor, mineralocorticoid receptor 1, mineralocorticoid receptor 2, mineralocorticoid receptor delta, Nuclear receptor subfamily 3 group C member 2
Uniprot ID
Mouse ortholog
Nr3c2 (110784)
mineralocorticoid receptor (Q8VII8)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Spironolactone
+
Hydrochlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Spironolactone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 23,337 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,783 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use